NCT02131636View on ClinicalTrials.gov

Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea

PHASE3CompletedINTERVENTIONAL
Enrollment

440

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

December 31, 2014

Conditions
ErythemaRosacea
Interventions
DRUG

AGN-199201

AGN-199201 applied to the face once daily for 29 days.

DRUG

Vehicle to AGN-199201

Vehicle to AGN-199201 applied to the face once daily for 29 days.

Trial Locations (1)

Unknown

Lynchburg

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY